Harmony (HRMY) news
Recent news
Harmony Acquisitions, Viny Pharma enter non-binding merger LOI
Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) has announced a definitive agreement to acquire Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), a company specializing in transdermal cannabinoid therapies for rare neuropsychiatric disorders. The transaction, which is subject to customary closing…
AInvest Wire · Aug 6, 2026Harmony: Wakix on track to achieve $1B-$1.04B FY net revenue
AInvest Wire · Aug 4, 2026Harmony Biosciences: Mizuho raises target price to $51 from $50
Mizuho Securities has raised its price target for Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) to $51 from $50, while maintaining an "Outperform" rating . This adjustment reflects the firm’s confidence in the company’s growth trajectory and strategic initiatives. Harmony Biosciences, a…
AInvest Wire · Aug 3, 2026Harmony Biosciences prelim 2Q net revenue for Wakix ~$261M
Harmony Biosciences reported preliminary net revenue for Wakix in the second quarter of 2026 of approximately $261 million [1]. This figure reflects the company’s performance in the treatment of hypocretin deficiency, a condition associated with narcolepsy. The data is preliminary and subject to…
AInvest Wire · Jul 16, 2026Harmony names Mollichel-la interim principal financial officer
AInvest Wire · Jul 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.